Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immuno deficiency Virus

Vol. 43 / No. RR-11

MMWR

17

21. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine
susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr
1990;3:743-6.
22. Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engi J Med
1993;328:1686-95.
23. Smith MS, Koerber KL, Pagano JS. Long-term persistence of zidovudine resistance mutations
in plasma isolates from human immunodeficiency virus type 1 of didexoyinosine-treated patients removed from zidovudine therapy. J Infect Dis 1994;169:184-8.
24. Chavanet P, Diquet B, Waldner A, Portier H. Perinatal pharmacokinetics of zidovudine [Letter].
N Engl J Med 1989;321:1548-9.
25. Lyman WD, Tankaka KE, Kress Y, Rubinstein A, Soeiro R. Zidovudine concentrations in human
fetal tissue: implications for perinatal AIDS [Letter]. Lancet 1990;335;1280-1.
26. Bernard N, Boulley AM, Perol R, Rouzioux C, Colau JC. Failure of zidovudine prophylaxis
after exposure to HIV-1 [Letter]. N EngI J Med 1990;323:916.
27. Barzilai A, Sperling RS, Hyatt AC, et al. Mother to child transmission of human immunodeficiency virus I infection despite zidovudine therapy from 18 weeks gestation. Pediatr Infect
Dis J 1990;9:931-3.
28. Mofenson LM, Wolinsky SM. Vertical transmission of HIV. Part C: current insights regarding
vertical transmission. In: Pediatric AIDS: the challenge of HIV infection in infants, children,
and adolescents. 2nd ed. Pizzo PA, Wilfert CM, eds. Baltimore MD: Williams & Wilkins,
1994:179-203.
29. De Gruttola V, Beckett LA, Coombs RW, et al. Serum p24 antigen level as an intermediate
end point in clinical trials of zidovudine in people infected with human immunodeficiency
virus type 1. J Infect Dis 1994;169:713-21.
30. Sande MA, Carpenter CCJ, Cobbs G, et al. Antiretroviral therapy for adult HIV-infected patients-recommendations from a state-of-the-art conference. JAMA 1993;270:2583-9.
31. Sperling RS, Stratton P, Obstetric Gynecologic Working Group of the AIDS Clinical Trials Group
of the National Institute of Allergy and Infectious Diseases. Treatment options for human immunodeficiency virus-infected pregnant women. Obstet Gynecol 1992;79:443-8.
32. St. Louis ME, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according
to maternal immunologic, virologic and placental factors. JAMA 1993;269:2853-9.
33. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet
1992;339:1007-12.
34. Ryder RW, Nsa W, Hassig SE, et al. Perinatal transmission of the human immunodeficiency
virus type 1 to infants of seropositive women in Zaire. N EngI J Med 1989;320:1637-42.
35. Burns DN, Landesman S, Muenz LR, et al. Cigarette smoking, premature rupture of membranes
and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune
Defic Syndr 1994;7:718-26.
36. Tibaldi C, Ziarati N, Salassa B, D'Ambrosio R, Sinicco A. Asymptomatic women at high risk
of vertical HIV-1 transmission to their fetuses. Br J Obstet Gynecol 1993;100:334-7.
37. Bulterys M, Chao A, Dushimimana A, et al. Multiple sexual partners and mother-to-child transmission of HIV-1. AIDS 1993;7:1639-45.
38. Pitt J, Landy A, McIntosh K, et al. Prenatal maternal circulating leukocyte HIV predisposes
to HIV culture positivity in their infants: progress from a North American cohort [Abstract
598] In: Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents
and Chemotherapy. Anaheim, CA: American Society for Microbiology, 1992.
39. Yerly S, Chamot E, Hirschel B, Perrin LH. Quantitation of human immunodeficiency virus
provirus and circulating virus: relationship with immunologic parameters. J Infect Dis
1992;166:269-76.
40. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance
mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect
Dis 1992;165:105-10.
41. Erice A, Balfour HH. Resistance of human immunodeficiency virus type 1 to antiretroviral
agents: a review. Clin Infect Dis 1994;18:149-56.
42. Tudor-Williams G, St. Clair MH, McKinney RE, et al. HIV-1 sensitivity to zidovudine and clinical
outcome in children. Lancet 1992;339:15-9.